A hidroxicloroquina, the medicine remdesivir, gives Gilead Sciences, and two other antivirals had little or almost no effect on hospitalization times or chances of survival for covid-19, concluded a study of World Health Organization (WHO).
The results are from the WHO “Solidarity” study, which evaluated the effects of four treatments with medications that included remdesivir, hydroxychloroquine, and the combination of lopinavir / ritonavir and interferon (used to treat HIV) in 11,266 patients adults in more than 30 countries.
The study, done in just six months, concluded that the protocols appeared to have little or no effect on reducing mortality in 28 days or on the duration of hospital treatment among patients hospitalized with covid-19, the WHO said on Thursday, 15 .
Remdesivir, one of the first to be used as a treatment for covid-19, was one of the remedies used to treat US President Donald Trump, after his coronavirus infection.
The research results will still be reviewed and were made available on the MedRxiv server before being published in a scientific journal.
New antiviral drugs, immunomodulators and antibodies against coronavirus should also be evaluated.
Earlier this month, data from a North American study with remdesivir by Gilead Sciences showed that the treatment cut the recovery time for covid-19 by five days when compared to patients who received placebo in a test involving 1,062 patients ./With information from REUTERS